Cancer Theranosis: Multimodal Cancer Theranosis Using Hyaluronate‐Conjugated Molybdenum Disulfide (Adv. Healthcare Mater. 1/2019) | Zendy

Shin MyeongHwan | Zendy; Park EunYeong | Zendy; Han Seulgi | Zendy; Jung Ho Sang | Zendy; Keum Do Hee | Zendy; Lee GeonHui | Zendy; Kim Taeyeon | Zendy; Kim Chulhong | Zendy; Kim Ki Su | Zendy; Yun Seok Hyun | Zendy; Hahn Sei Kwang | Zendy

Premium

Cancer Theranosis: Multimodal Cancer Theranosis Using Hyaluronate‐Conjugated Molybdenum Disulfide (Adv. Healthcare Mater. 1/2019)

Author(s) -

Shin MyeongHwan,

Park EunYeong,

Han Seulgi,

Jung Ho Sang,

Keum Do Hee,

Lee GeonHui,

Kim Taeyeon,

Kim Chulhong,

Kim Ki Su,

Yun Seok Hyun,

Hahn Sei Kwang

Publication year - 2019

Publication title -

advanced healthcare materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.288

H-Index - 90

eISSN - 2192-2659

pISSN - 2192-2640

DOI - 10.1002/adhm.201970002

Subject(s) - conjugate , conjugated system , molybdenum disulfide , photothermal therapy , materials science , nanotechnology , combinatorial chemistry , chemistry , polymer , metallurgy , mathematical analysis , mathematics , composite material

In article number 1801036 , Ki Su Kim, Sei Kwang Hahn, and co‐workers develop hyaluronate conjugated molybdenum disulfide (HA‐MoS 2 conjugate) for targeted cancer theranosis. The HA‐MoS 2 conjugate can be successfully used for both photoacoustic and fluorescence imaging. In addition, upon NIR light illumination, HA‐MoS 2 conjugate enables highly effective target‐specific photothermal cancer therapy. Taken together, HA‐MoS 2 conjugate appears to show a great potential for various theranostic applications.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research